Effects of Telbivudine and Lamivudine on Hepatitis B Serum Antigen in Patients with Chronic Hepatitis B

李春玉,张学武,胡国启,段振乾,张彦

DOI: https://doi.org/10.3969/j.issn.1005-0264.2010.03.004

2010-01-01

Abstract:Objective:To observe and compare the efficacy of telbivudine and lamivudine in patients with chronic hepatitis B and their effects on the serum protein levels of hepatitis B antigen.Methods:With 1∶1 randomized,controlled design,a total of 100 patients with chronic hepatitis B were enrolled and randomly divided into the telbivudine group of 50 patients and 50 patients with lamivudine group.The clinical efficacy and adverse reactions of the two groups were observed in control,and dynamics of serum HBsAg,HBeAg levels were monitored and compared .Results:One year of treatment,the negative rate of semm HBV DNA levels( PCR-undetectable ,1000 copies/ml),and ALT normalization rate in telbivudine group was slightly higher than the lamivudine group,but there were no statistical significance;HBeAg serum negative rates and conversion rates and viral breakthrough rate were 34%,28% and 8%,better than the lamivudine group with 16%,12% and 22%,respectively,the difference had statistically significance(P=0.0377,0.0455 and 0.0498,respectively).After the begining of treatment,serum HBsAg and HBeAg had different levels of decline,but in treatment 1 month, the level of serum HBsAg and HBeAg in telbivudine treatment group decreased from with baseline were (30.2±16.1) S / N,and (80.8±12.9) S / CO higher than the lamivudine group (7.8±12.4) S/ N,and (10.9±27.9)S / CO,the difference had statistically significance(P=0.005 and 0.05 respectively).To treatment 12 months,its decline was more difference obviously,respectively (146.7±32.5)S / N,(202.3±62.8) S/CO and (68.4±39.5)S/N,(90.4±52.8)S/CO(P=0.000 and 0.000 respectively),the differences had more statistically significance .For telbivudine,adverse reactions were mild,similar to lamivudine.Conclusion:Telbivudine is significant superior to lamivudine with respect to strong suppression of HBV DNA replication and less resistance to the nucleosides as well as viral breakthrough.While telbivudine to stronger inhibition of virus antigen expression may be related to higher rates of HBeAg seroconversion.